OPTN News and Press, OptiNose Inc. From 09/22/23

YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 2...

2023-08-10 12:23:02 ET OptiNose Inc. (OPTN) Q2 2023 Earnings Conference Call August 10, 2023 08:00 AM ET Company Participants Jonathan Neely - VP, IR and Business Operations Ramy Mahmoud - CEO Paul Spence - CCO Conference Call Participants Presentat...

2023-08-10 07:02:54 ET OptiNose press release ( NASDAQ: OPTN ): Q2 GAAP EPS of $0.02 beats by $0.13 . Revenue of $19.45M (-5.6% Y/Y) beats by $2.45M . For further details see: OptiNose GAAP EPS of $0.02 beats by $0.13, revenue of $19.45M beats by $2.45M

Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency in the first half of 2023 as SG&A and R&D expenses decreased by $22M or 33% compared to first hal...

2023-08-01 18:58:32 ET Summary On August 10, OptiNose, one of the leaders in the global chronic rhinosinusitis market, will publish its financial results for the 2nd quarter of 2023. OptiNose's preliminary net revenue for the second quarter of 2023 was $19.5 million, up 65.3% from...

Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE net revenue guidance on August 10 YARDLEY, Pa., July 27, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company...

YARDLEY, Pa., June 16, 2023 (GLOBE NEWSWIRE) -- OptiNose , Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option award to purchase 100,000 shares...

YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Je...

2023-05-19 12:49:26 ET Gainers: Mallinckrodt ( MNK ) +251% . Biocept ( BIOC ) +47% . WISeKey International Holding ( WKEY ) +41% . Aemetis ( AMTX ) +33% . Crescera Capital Acquisition ( CREC ) +32% . Stereotaxis ( STXS ) ...

2023-05-11 17:57:10 ET OptiNose Inc. (OPTN) Q1 2023 Results Conference Call May 11, 2023 08:00 AM ET Company Participants Jonathan Neely - VP of IR and Business Operations Ramy Mahmoud - CEO and Director Conference Call Participants Brandon Folkes - Canto...